PMON30 Low-dose Infigratinib, an Oral Selective Fibroblast Growth Factor Receptor Tyrosine Kinase Inhibitor, Demonstrates Activity in a Preclinical Model of Hypochondroplasia

BACKGROUND: Fibroblast growth factor receptor 3 (FGFR3) gain-of-function mutations play a crucial role in achondroplasia (ACH), thanatophoric dysplasia (TD), and hypochondroplasia (HCH). HCH is a less severe form of dwarfism than ACH, but similarly is caused by gain-of-function mutations in the FGFR...

Descripción completa

Detalles Bibliográficos
Autores principales: Dambkowski, Carl, Demuynck, Benoit, Legeai-Mallet, Laurence, Loisay, Léa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Genetics & Development
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625608/
http://dx.doi.org/10.1210/jendso/bvac150.956

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625608/
http://dx.doi.org/10.1210/jendso/bvac150.956

Ejemplares similares